The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
Abstract
PURPOSE: To determine the maximum-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 weeks. PATIENTS AND METHODS: Twenty-seven patients with a median age of 58 years received 85 cycles of R115777 using an intrapatient and interpatient dose escalation schema. Drug was administered orally at escalating doses as a solution (25 to 850 mg bid) or as pellet capsules (500 to 1300 mg bid). Pharmacokinetics were assessed after the first dose and the last dose administered during cycle 1. RESULTS: Dose-limiting toxicity of grade 3 neuropathy was observed in one patient and grade 2 fatigue (decrease in two performance status levels) was seen in four of six patients treated with 1,300 mg bid. The most frequent clinical grade 2 or 3 adverse events in any cycle included nausea, vomiting, headache, fatigue, anemia, and hypotension. Myelosuppression was mild and infrequent. Peak plasma concentrations of R115777 were achieved within 0.5 to 4 hours after oral drug administration. The elimination of R115777 from plasma was biphasic, with sequential half-lives of about 5 hours and 16 hours. There was little drug accumulation after bid dosing, and steady-state concentrations were achieved within 2 to 3 days. The pharmacokinetics were dose proportional in the 25 to 325 mg/dose range for the oral solution. Urinary excretion of unchanged R115777 was less than 0.1% of the oral dose. One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiographically stable disease for 5 months. CONCLUSION: R115777 is bioavailable after oral administration and has an acceptable toxicity profile. Based upon pharmacokinetic data, the recommended dose for phase II trials is 500 mg orally bid (total daily dose, 1,000 mg) for 5 consecutive days followed by 9 days of rest. Studies of continuous dosing and studies of R115777 in combination with chemotherapy are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Detection of high incidence of K-ras oncogenes during human colon tumorigenesis
Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., & Perucho, M. (1987) · Nature · doi:10.1038/327298a0 · Cited by 1,061
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 817
Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton
Tapon, N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80156-1 · Cited by 814
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Downward, J. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80061-0 · Cited by 555
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540
Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., & Der, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6403 · Cited by 540
Gutierrez, L., Magee, A. I., Marshall, C. J., & Hancock, J. F. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03478.x · Cited by 460
Sepp‐Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, W. W., Oliff, A. I., & Rosen, N. X. (1995) · PubMed · Cited by 383
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338
Proliferation of human malignant astrocytomas is dependent on Ras activation
Guha, A., Feldkamp, M. M., Lau, N., Boss, G., & Pawson, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337
Hakim, F. T., Cepeda, R., Kaimei, S., Mackall, C. L., McAtee, N., Zujewski, J., Cowan, K., & Gress, R. E. (1997) · Blood · doi:10.1182/blood.v90.9.3789 · Cited by 323
Self-citationLiu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas
Grünewald, K., Lyons, J., Fröhlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W. G., & Bartram, C. R. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430614 · Cited by 290
James, G. L., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6221 · Cited by 290
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Du, W., Lebowitz, P. F., & Prendergast, G. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1831 · Cited by 248
T-cell regeneration: all repertoires are not created equal
Mackall, C. L., Hakim, F. T., & Gress, R. E. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)81664-7 · Cited by 234
Self-citationSun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · PubMed · Cited by 227
Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.
Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., & Lewis, M. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46638-5 · Cited by 220
Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB
Lebowitz, P. F., Casey, P. J., Prendergast, G. C., & Thissen, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15591 · Cited by 216
A- and B-type lamins are differentially expressed in normal human tissues
Broers, J. L. V., Machiels, B. M., Kuijpers, H. J. H., Smedts, F., van den Kieboom, R., Raymond, Y., & Ramaekers, F. C. S. (1997) · Histochemistry and Cell Biology · doi:10.1007/s004180050138 · Cited by 216
Aberrant function of the Ras signal transduction pathway in human breast cancer
Clark, G. J., & Der, C. J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00694753 · Cited by 213
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D.-S., Danishefsky, S. J., & Rosen, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1369 · Cited by 210
Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4193 · Cited by 209
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
Janes, P. W., Daly, R. J., DeFazio, A., & Sutherland, R. L. (1994) · PubMed · Cited by 199
Bernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J., & Muschel, R. J. (1998) · PubMed · Cited by 195
CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoB
Armstrong, S. A., Hannah, V. C., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7864 · Cited by 164
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
Peli, J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1824 · Cited by 159
Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma
(1995) · Lung Cancer · doi:10.1016/0169-5002(95)90161-2 · Cited by 158
Nociari, M., Telford, W. G., & Russo, C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3327 · Cited by 154
Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lü, S., Malumbres, M., Gibbs, W. W., Oliff, A. I., & Pellicer, À. (1998) · PubMed · Cited by 146
Yokoyama, K., McGeady, P., & Gelb, M. H. (1995) · Biochemistry · doi:10.1021/bi00004a029 · Cited by 138
Knowles, M. A., & Williamson, M. P. (1993) · PubMed · Cited by 131
Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan, N., Ricca, C. S., Fletcher, J. A., Glover, T. W., Seizinger, B. R., & Manne, V. (1995) · PubMed · Cited by 129
Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity.
Der, C. J., & Cox, A. D. (1991) · PubMed · Cited by 124
d’Angeac, A. D., Monier, S., Pilling, D., Travaglio‐Encinoza, A., Reme, T. X., & Salmon, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240707 · Cited by 96
Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction
Ward, R. L., Hawkins, N. J., O'grady, R., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65581-2 · Cited by 76
Activated protooncogenes in human lung tumors from smokers.
Reynolds, S. H., Anna, C. K., Brown, K., Wiest, J. S., Beattie, E. J., Pero, R. W., Iglehart, J. D., & Anderson, M. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1085 · Cited by 69
Patton, S. E., Martin, M. L., Nelsen, L., Fang, X., Mills, G. B., Bast, R. C., & Ostrowski, M. C. (1998) · PubMed · Cited by 58
Gomez, J., González-Garcı́a, A., Martínez‐A, C., & Rebollo, A. (1998) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v18.i3.20 · Cited by 43
Pittler, S. J., Fliesler, S. J., Fisher, P. L., Keller, P., & Rapp, L. M. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.130.2.431 · Cited by 43
Prenoids and palmitate: lipids that control the biological activity of Ras proteins.
Kato, K., Der, C. J., & Buss, J. E. (1992) · PubMed · Cited by 26
Cited by
Blocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Metadata
- Authors
- Zujewski, J., Horak, I. D., Bol, C. J., Woestenborghs, R., Bowden, C., End, D. W., Piotrovsky, V. K., Chiao, J., Belly, R. T., Todd, A., Kopp, W. C., Kohler, D. R., Chow, C., Noone, M., Hakim, F. T., Larkin, G., Gress, R. E., Nussenblatt, R. B., Kremer, A. B., & Cowan, K. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-14
- Volume
- 18
- Issue
- 4
- Pages
- 927-927
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2255894651
- Cited by
- 264
- References
- 55
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.